Acarix AB

7AC

Company Profile

  • Business description

    Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.

  • Contact

    Hyllie Boulevard 34
    Regus Malmo
    Malmo215 32
    SWE

    https://www.acarix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    8

Stocks News & Analysis

stocks

Investors again disappointed by ASX bank result

Solid result but valuation is stretched.
stocks

Big-four bank earnings surge but revenue growth elusive

Shares sell off after results.
stocks

This ASX supermarkets business is now underperforming its largest competitor

Competition restrains long-term margins.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,983.3024.600.27%
CAC 408,062.3186.191.08%
DAX 4024,401.70410.431.71%
Dow JONES (US)49,298.25356.350.73%
FTSE 10010,219.11144.82-1.40%
HKSE25,898.61197.27-0.76%
NASDAQ25,326.13258.331.03%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,194.19158.491.22%
S&P 5007,259.2258.470.81%
S&P/ASX 2008,762.8027.800.32%
SSE Composite Index4,112.140.01-0.00%

Market Movers